Scholarlink

Purpose <p>We evaluated the performance of CHROMAgar™LIN-R agar plates as part of a multicenter study (“APPLE”).</p> Methods <p>The study was performed using 1200 rectal swabs and stool samples.</p> Results <p>We identified 168 enterococci with 75.6% (127/168) confirmed as linezolid-resistant (LRE) by the disc diffusion method. Among these, 48 LRE were single-patient isolates, of which 75% (36/48) showed resistance to vancomycin and 4.2% (2/48) to vancomycin and tigecycline. Overall LRE prevalence was 4.3% (48/1113) with the highest prevalence at adult hematology wards (11.3%). False-positivity rate was 24.4% (41/168) and significantly lower in neurological intensive care and hematology departments compared to pediatric hematology (adjusted&#xa0;<i>p</i>&#xa0;= 0.0034&#xa0;and&#xa0;<i>p</i>&#xa0;= 0.0014, respectively). Prevalence was significantly higher in stool samples&#xa0;(8.8% vs. 1.6%) (<i>p</i>&#xa0;&lt; 0.0001).</p> Conclusion <p>Assessing the performance of CHROMAgar™LIN-R among different patient groups and sample types may enhance its application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Performance of CHROMAgar™ LIN-R screening medium for the detection of linezolid-resistant enterococci in Croatian tertiary care hospital

  • 期刊论文

  • 发表日期：

    2025年10月13日

查看全文
  • Mislav Peras,
  • Jennifer Karin Bender,
  • Guido Werner,
  • Lucija Brechelmacher,
  • Tomislav Kuliš,
  • Ivana Mareković

摘要

Purpose

We evaluated the performance of CHROMAgar™LIN-R agar plates as part of a multicenter study (“APPLE”).

Methods

The study was performed using 1200 rectal swabs and stool samples.

Results

We identified 168 enterococci with 75.6% (127/168) confirmed as linezolid-resistant (LRE) by the disc diffusion method. Among these, 48 LRE were single-patient isolates, of which 75% (36/48) showed resistance to vancomycin and 4.2% (2/48) to vancomycin and tigecycline. Overall LRE prevalence was 4.3% (48/1113) with the highest prevalence at adult hematology wards (11.3%). False-positivity rate was 24.4% (41/168) and significantly lower in neurological intensive care and hematology departments compared to pediatric hematology (adjusted p = 0.0034 and p = 0.0014, respectively). Prevalence was significantly higher in stool samples (8.8% vs. 1.6%) (p < 0.0001).

Conclusion

Assessing the performance of CHROMAgar™LIN-R among different patient groups and sample types may enhance its application.